These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22907381)

  • 1. Design and production of multimeric antibody fragments, focused on diabodies with enhanced clinical efficacy.
    Powers GA; Hudson PJ; Wheatcroft MP
    Methods Mol Biol; 2012; 907():699-712. PubMed ID: 22907381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.
    Kortt AA; Dolezal O; Power BE; Hudson PJ
    Biomol Eng; 2001 Oct; 18(3):95-108. PubMed ID: 11566601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
    Todorovska A; Roovers RC; Dolezal O; Kortt AA; Hoogenboom HR; Hudson PJ
    J Immunol Methods; 2001 Feb; 248(1-2):47-66. PubMed ID: 11223068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
    Albrecht H; Denardo GL; Denardo SJ
    J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
    Albrecht H; Burke PA; Natarajan A; Xiong CY; Kalicinsky M; DeNardo GL; DeNardo SJ
    Bioconjug Chem; 2004; 15(1):16-26. PubMed ID: 14733579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High avidity scFv multimers; diabodies and triabodies.
    Hudson PJ; Kortt AA
    J Immunol Methods; 1999 Dec; 231(1-2):177-89. PubMed ID: 10648937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designer genes: recombinant antibody fragments for biological imaging.
    Wu AM; Yazaki PJ
    Q J Nucl Med; 2000 Sep; 44(3):268-83. PubMed ID: 11105590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris.
    Marty C; Scheidegger P; Ballmer-Hofer K; Klemenz R; Schwendener RA
    Protein Expr Purif; 2001 Feb; 21(1):156-64. PubMed ID: 11162401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New type recombinant antibody fragment scFv multimer and cancer targeting].
    Guo J; Cai M
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):361-5. PubMed ID: 12856620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered antibody fragments and the rise of single domains.
    Holliger P; Hudson PJ
    Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triabodies: single chain Fv fragments without a linker form trivalent trimers.
    Iliades P; Kortt AA; Hudson PJ
    FEBS Lett; 1997 Jun; 409(3):437-41. PubMed ID: 9224705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging.
    Power BE; Hudson PJ
    J Immunol Methods; 2000 Aug; 242(1-2):193-204. PubMed ID: 10986400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered single chain antibody fragments for radioimmunotherapy.
    Huhalov A; Chester KA
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
    Weisser NE; Hall JC
    Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains.
    Kim YJ; Neelamegam R; Heo MA; Edwardraja S; Paik HJ; Lee SG
    J Microbiol Biotechnol; 2008 Jun; 18(6):1186-90. PubMed ID: 18600066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
    Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
    Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
    Schier R; Bye J; Apell G; McCall A; Adams GP; Malmqvist M; Weiner LM; Marks JD
    J Mol Biol; 1996 Jan; 255(1):28-43. PubMed ID: 8568873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.